logo
  

Seagen, Astellas, Merck: EV-103 Results Support Investigation Of Enfortumab Vedotin, Pembrolizumab

Seagen Inc. (SGEN), Astellas Pharma Inc. and Merck (MRK) reported results from the phase 1b/2 EV-103 clinical trial Cohort K investigating PADCEV, or enfortumab vedotin-ejfv, in combination with Merck's anti-PD-1 therapy KEYTRUDA or pembrolizumab and PADCEV alone as first-line treatment in patients with unresectable locally advanced or metastatic urothelial cancer who are ineligible to receive cisplatin-based chemotherapy. Overall, the results were generally consistent with previously reported efficacy and safety results of EV-103 dose-escalation cohort and expansion cohort A.

"Nearly sixty-five percent of patients who were treated with enfortumab vedotin and pembrolizumab responded to the combination, with almost eleven percent showing no detectable cancer following treatment," said Marjorie Green, Senior Vice President and Head of Late-Stage Development, Seagen.

Seagen, Astellas and Merck are further investigating enfortumab vedotin plus pembrolizumab in phase 3 studies.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple Inc. plans to start using American-made processors from the new advanced chip factory in Phoenix, Arizona operated by chip giant Taiwan Semiconductor Manufacturing Co., according to its Chief Executive Officer Tim Cook. At an event in the factory in Arizona, which was attended by U.S. President Joe Biden, it was also announced that TSMC will invest $40 billion in the new factory. Lidl US has recalled its 8.4 oz Favorina branded Advent Calendar, i.e., Premium Chocolate with a Creamy Filling, citing potential Salmonella contamination, the U.S. Food and Drug Administration said. The products were available for sale at Lidl stores between October 12, 2022 and December 5, 2022. They will have a BEST IF USED BY year of 2023, and barcode number of 4056489516965. Vaccine partners Pfizer Inc. and BioNTech SE are seeking emergency use authorization or EUA from the U.S. Food and Drug Administration to offer their bivalent COVID-19 vaccine to children 6 months through 4 years of age. If authorized, the vaccine would be part of a primary series for children in this age group.
Follow RTT